Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Kiadis Pharma NV (KDS) EUR0.10

Sell:€2.95 Buy:€3.02 Change: €0.024 (0.79%)
Market closed |  Prices as at close on 22 November 2019 | Switch to live prices |
Sell:€2.95
Buy:€3.02
Change: €0.024 (0.79%)
Market closed |  Prices as at close on 22 November 2019 | Switch to live prices |
Sell:€2.95
Buy:€3.02
Change: €0.024 (0.79%)
Market closed |  Prices as at close on 22 November 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Kiadis Pharma NV is a clinical stage biopharmaceutical company based in the Netherlands. It focuses on research and development of cell-based immunotherapy products for the treatment of blood cancer (leukemia) and inherited blood disorders, such as thalassemia. The Company develops products that provide for Allodepleted T-cell ImmunotheRapeutics (ATIR) and are based on the Theralux platform. The Company develops ATIR101 and ATIR201, which are designed to support the patient’s newly transplanted immune system before it becomes fully functional. The Company's products address risks and limitations of hematopoietic stem cell transplantation (HSCT) in blood cancers, such as opportunistic infections, Graft-versus-Host-Disease (GVHD), cancer relapse and limited donor availability.

Contact details

Address:
Paasheuvelweg 25A
AMSTERDAM
1105 BP
Netherlands
Telephone:
+31 (20) 2405250
Website:
www.kiadis.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
KDS
ISIN:
NL0011323407
Market cap:
€89.34 million
Shares in issue:
29.56 million
Sector:
Biotechnology
Exchange:
Euronext Amsterdam
Country:
Netherlands
Currency:
Euro
Indices:
n/a

Key personnel


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.